###### Key questions

What is already known?
======================

-   Herpes simplex virus type 1 (HSV-1) infection is typically acquired through oral transmission during childhood.

-   Recent data from North America and Europe suggest a decrease in acquisition of HSV-1 in childhood, a decline in seroprevalence in youth and an increase in genital herpes cases that are caused by HSV-1.

What are the new findings?
==========================

-   Only two-thirds of the population in Europe are HSV-1 seropositive, far lower than the historical level of universal infection in childhood.

-   Two-thirds of European children are reaching sexual debut unexposed to this infection, and at risk of genital acquisition in adulthood.

-   Half of first episode genital herpes cases in Europe are already due to HSV-1, as opposed to HSV-2 infection.

-   Seroprevalence in Europe is declining by 1% per year, and the contribution of HSV-1 to genital herpes is increasing, also by 1% per year.

What do the new findings imply?
===============================

-   HSV-1 epidemiology in Europe is in transition and shifting away from its historical pattern of oral acquisition in childhood.

-   HSV-1 transition in Europe is leading to more heterogeneous and variable transmission by age and geography, and an increasing role for HSV-1 in genital herpes and as a sexually transmitted disease.

-   The findings highlight the importance of disease surveillance and monitoring of HSV-1 seroprevalence and genital herpes aetiology, and strengthen the case for an HSV-1 vaccine to limit transmission.

Introduction {#s1}
============

Herpes simplex virus type 1 (HSV-1) causes a latent and mostly asymptomatic infection, and is typically acquired orally during childhood.[@R1] Infection is lifelong, with most viral shedding occurring through subclinical short-duration reactivations on the oral mucosa.[@R3] When symptomatic, HSV-1 can result in a number of adverse outcomes and sequelae such as mucocutaneous conditions and central nervous system complications.[@R1] The historical pattern of HSV-1 epidemiology appears to be changing, at least in a few regions.[@R4] Studies show a decrease in early acquisition of HSV-1, a decline in seroprevalence among youths and an increase in genital herpes cases caused by HSV-1.[@R4] The disease burden of this infection, alongside its evolving epidemiology, has drawn the attention of the World Health Organization (WHO) and global partners, who are leading an international multisectorial effort focused on understanding the epidemiology of the virus and developing a HSV vaccine.[@R18]

Under this guise, we conducted a comprehensive systematic review to characterise HSV-1 epidemiology in Europe. We also used meta-analytical methods to provide robust estimates for HSV-1 seroprevalence across different populations, as well as proportions of HSV-1 detection in genital ulcer disease (GUD) and in genital herpes. We further assessed associations and temporal trends for these outcome measures.

Methods {#s2}
=======

The methodology of this study was adapted from a previously conducted systematic review investigating the epidemiology of HSV-1 in Asia.[@R9] Details of the methodology are described in [table 1](#T1){ref-type="table"}.

###### 

Detailed methodology for this study

  Methodology                                            Detailed description
  ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Data source and search strategy                        Search conducted on 16 September 2019 in PubMed and EmbaseSearch strategies included exploded MeSH/Emtree terms and broad terms with no language or time restrictionThe definition of Europe included 53 countries stratified by European subregion/country:Eastern Europe: Belarus, Bulgaria, Czech Republic, Hungary, Poland, Republic of Moldova, Romania, Russian Federation, Slovakia and Ukraine.Northern Europe: Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden and UKSouthern Europe: Albania, Andorra, Bosnia and Herzegovina, Croatia, Greece, Italy, Malta, Montenegro, Portugal, Republic of Macedonia, San Marino, Serbia, Slovenia and SpainWestern Europe: Austria, Belgium, France, Germany, Luxembourg, Monaco, The Netherlands and SwitzerlandIntersection of Europe and Asia: Armenia, Azerbaijan, Cyprus, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and UzbekistanIsraelTurkey
  Study selection and inclusion and exclusion criteria   Search results were imported into the reference manager Endnote (Thomson Reuters, USA)Screening was performed in four stages:Duplicate publications were identified and excludedTitles and abstracts were screened for relevant and potentially relevant publicationsFull texts of relevant and potentially relevant publications were retrieved and screened for relevanceBibliographies of relevant publications and reviews were checked for additional potentially relevant publicationsInclusion criteria were any publication, with a minimum sample size of 10, reporting primary data on any of the following outcome measures:HSV-1 seroprevalence as detected by a type specific diagnostic assayProportion of HSV-1 in GUD, as detected by standard viral detection and subtyping methodsProportion of HSV-1 in genital herpes (as opposed to HSV-2), as detected by standard viral detection and subtyping methodsExclusion criteria were:Case reports, case series, reviews, editorials, commentaries and qualitative studiesMeasures reporting seroprevalence in infants aged \<6 months as their antibodies are maternal in origin
  Data extraction and data synthesis                     Extracted variables included: author(s), publication title, year(s) of data collection, publication year, country of origin, country of survey, city, study site, study design, study sampling procedure, study population and its characteristics (eg, sex and age), sample size, HSV-1 outcome measures and diagnostic assayFor studies including overall sample size, but no individual strata sample sizes, the sample size of each stratum was assumed equal to overall sample size divided by the number of strata in the studyStratification hierarchy for seroprevalence in descending order of preference were population type, age bracket and age group:Population type classified as:Healthy general populations: healthy populations such as blood donors, pregnant women and outpatients with minor health conditionsClinical populations: any population with a major clinical condition, or a condition related (potentially) to HSV-1 infectionOther populations: other populations not satisfying above definitions, or populations with an undetermined risk of acquiring HSV-1, such as HIV positive patients, sex workers, men who have sex with men and prisonersAge category classified as:Children: age ≤15 yearsAdults: age \>15 yearsAge group classified as (groups optimised to best fit reported data):\<20 years20--30 years30--40 years40--50 years\>50 yearsStratification hierarchy for GUD and genital herpes included genital herpes episode status and study site:Genital herpes episode status classified as:First episode genital herpesRecurrent genital herpesStudy site stratification classified as:HospitalSexually transmitted disease clinic
  Quality assessment                                     The Cochrane's approach for risk of bias assessment included:Study's precision classification into low vs high based on the sample size (\<100 vs ≥100)Study's appraisal into low vs high risk of bias was determined using two quality domains:Sampling method: probability based vs non-probability basedResponse rate: ≥80% vs \<80% or unclear
  Meta-analyses                                          Meta-analyses were conducted using the DerSimonian--Laird random effects models with inverse variance weighting. The variance of each outcome measure was stabilised using the Freeman--Tukey double arcsine transformationPooled means HSV-1 seroprevalence were estimated by age bracket, age group, European subregion/country, population type, genital herpes episode status, sex and year of publication range.Pooled proportions of HSV-1 detection in genital herpes cases were estimated by age group, European subregion/country, sex and year of publication range.Overall pooled proportion of HSV-1 detection in GUD cases was estimatedHeterogeneity assessment was based on three complementary metrics:Cochran's Q statistic to assess existence of heterogeneity in effect size (p value \<0.1 indicated heterogeneity)I^2^ heterogeneity measure to assess the percentage of between study variation in effect size that is due to actual differences in effect size rather than chancePrediction interval to describe the distribution of true outcome measures around the pooled mean
  Meta-regressions                                       Univariable and multivariable random effects meta-regression analyses using log transformed proportions were carried out to identify predictors of HSV-1 seroprevalence and HSV-1 proportion in genital herpesFactors in the univariable model with a p value \<0.1 were included in the multivariable analysisFactors in the multivariable model with a p value ≤0.05 were deemed to be significant predictorsVariables included in the meta-regression models for HSV-1 seroprevalence were:Age bracketAge groupSexPopulation typeEuropean subregion/countryCountry's income: upper middle income countries and high income countries according to the World Bank classification, for countries with available dataAssay type (western blot, ELISA and others)Sample sizeSampling methodResponse rateYear of publicationYear of publication range (\<2000; 2000--2010; \>2010)Variables included in the meta-regression models for proportion of HSV-1 detection in genital herpes were:Age groupSexGenital herpes episode statusEuropean subregion/countrySample sizeYear of publicationYear of publication range

ELISA, enzyme linked immunosorbent type specific assay; GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2.

Patient and public involvement {#s2-1}
------------------------------

Patients were not involved in this study.

Data sources and search strategy {#s2-2}
--------------------------------

This systematic review followed the Cochrane Collaboration Handbook[@R21] and reported its findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines (see online [supplementary table s1](#SP1){ref-type="supplementary-material"}).[@R22] We conducted a systematic literature search to identify HSV-1 related publications in Europe. Europe's definition and subregional classification were informed by the WHO and the United Nations Geoscheme, respectively[@R23] (see details in [table 1](#T1){ref-type="table"}). The search strategies used can be found in online [supplementary box s1](#SP1){ref-type="supplementary-material"}.
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Study selection and inclusion and exclusion criteria {#s2-3}
----------------------------------------------------

WY and HI conducted the initial screening, and MH conducted the double screening, as detailed in [table 1](#T1){ref-type="table"}. In this review, the term \'publication\' refers to a document reporting one or several overall outcome measures in one or several (different) populations. \'Study\' or \'measure\' refers to a specific outcome measure and its details.

Data extraction and data synthesis {#s2-4}
----------------------------------

Extraction and double extraction of relevant data were conducted. Extracted variables are listed in [table 1](#T1){ref-type="table"}. Overall outcome measures and their strata were extracted based on a preset hierarchy, provided the sample size in each stratum was ≥10 ([table 1](#T1){ref-type="table"}). Strata of outcome measures were extracted for more statistical power in assessing predictors of heterogeneity in effect size.

Quality assessment {#s2-5}
------------------

An initial quality assessment of relevant publications was conducted to assess the validity of the diagnostic assay in each study, given documented limitations.[@R25] Professor Rhoda Ashley-Morrow, an expert advisor from the University of Washington, evaluated the validity, sensitivity, and specificity of the assays. Only studies with valid and reliable assays were included in the systematic review. The precision and quality of each study were subsequently evaluated using the Cochrane approach for risk of bias (ROB) assessment[@R21] ([table 1](#T1){ref-type="table"}).

Meta-analyses {#s2-6}
-------------

We conducted meta-analyses in R V.3.4.1[@R27] using the DerSimonian--Laird random effects models and the Freeman--Tukey double arcsine transformation,[@R28] as listed in the meta package,[@R30] whenever ≥3 measures were available. This methodology was selected as it accounts for sampling variation and heterogeneity in effect size[@R28] (see [table 1](#T1){ref-type="table"}).

A sensitivity analysis was conducted using logit transformation instead of the Freeman--Tukey double arcsine transformation, in view of the recently identified issue for the latter transformation.[@R31] A second sensitivity analysis was conducted using a multilevel meta-analytic model[@R32] to account for potential dependence in measures extracted from the same study.

Meta-regressions {#s2-7}
----------------

We regressed log transformed seroprevalence and log transformed GUD/genital herpes proportions in Stata/SE V.13,[@R33] using the metareg package.[@R34] We used log transformation because we needed to estimate the risk ratios and not the odds ratios---HSV-1 seroprevalence is very high and thus the odds ratios may not be as meaningful. Univariable and multivariable random effects meta-regression analyses were conducted to identify sources of between study heterogeneity and predictors of outcomes ([table 1](#T1){ref-type="table"}). A sensitivity analysis was conducted using a multilevel meta-analytic model[@R32] to account for potential dependence in measures extracted from the same study.

Results {#s3}
=======

Search results and scope of evidence {#s3-1}
------------------------------------

[Figure 1](#F1){ref-type="fig"} describes the study selection process based on PRISMA guidelines.[@R22] The search identified 5803 citations (PubMed=1309 and Embase=4494). After performing the first two stages of the screening process, 912 citations were relevant or potentially relevant. The full text screening of these citations identified 135 relevant publications, and a further 7 relevant publications were identified through bibliography screening, including country level reports and articles in non-indexed journal.[@R35]

![Flowchart of article selection for the systematic review of herpes simplex virus type 1 (HSV-1) infection in Europe, according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.[@R22]](bmjgh-2020-002388f01){#F1}

In total, 142 publications met the inclusion criteria. The extracted outcome measures were: 179 overall and 622 stratified HSV-1 seroprevalence measures; 4 overall proportions of HSV-1 detection in GUD, and 62 overall and 161 stratified proportions of HSV-1 detection in genital herpes.

HSV-1 seroprevalence overview {#s3-2}
-----------------------------

[Online supplementary tables S2, S3 and S4](#SP1){ref-type="supplementary-material"} list the overall seroprevalence measures (number of measures (n)=179). The earliest publication was published in 1972. Studies were mainly cross sectional (n=117; 65.4%) and based on convenience sampling (n=133; 74.3%).

Stratified seroprevalence measures across all studies (n=622) ranged between 0.0% and 100% with a median of 70.0% ([table 2](#T2){ref-type="table"}). In healthy general populations, HSV-1 seroprevalence ranged between 0.0% and 82.0% with a median of 31.0% among children (n=101), and between 20.0% and 100% with a median of 73.6% among adults (n=402). In clinical populations, HSV-1 seroprevalence ranged between 31.0% and 52.0% with a median of 36.0% among children (n=3), and between 0.0% and 100% with a median of 73.3% among adults (n=59). A summary of HSV-1 seroprevalence measures across various populations and subpopulations is shown in [table 2](#T2){ref-type="table"}.

###### 

Pooled mean estimates for herpes simplex virus type 1 seroprevalence in Europe

  Population                         Outcome measure   Sample    HSV-1 seroprevalence   Pooled mean HSV-1 seroprevalence   Heterogeneity measures                                               
  ---------------------------------- ----------------- --------- ---------------------- ---------------------------------- ------------------------ --------------------- --------------------- ------------
  Healthy general populations                                                                                                                                                                   
   Children                          101               23 948    0.0--82.0              31.0                               32.4 (29.2 to 35.6)      2689.7 (p\<0.001)     96.3 (95.9 to 96.7)   7.0--65.3
   Adults                            402               105 523   20.0--100              73.6                               73.7 (71.9 to 75.4)      13 302.3 (p\<0.001)   97.5 (97.4 to 97.7)   36.0--98.1
   Age mixed                         13                5985      30.4--68.6             53.7                               54.3 (47.4 to 61.0)      301.1 (p\<0.001)      96.0 (94.5 to 97.1)   27.4--79.9
   All healthy general populations   516               135 456   0.0--100               68.0                               65.5 (63.3 to 67.6)      35 415.7 (p\<0.001)   98.5 (98.5 to 98.6)   17.8--98.9
  Clinical populations                                                                                                                                                                          
   Clinical children                 3                 149       31.0--52.0             36.0                               37.8 (28.3 to 47.8)      2.5 (p=0.281)         21.3 (0.0 to 91.8)    0.0--100
   Clinical adults                   59                11 071    0.0--100               73.3                               73.8 (68.9 to 78.5)      1770.0 (p\<0.001)     96.7 (96.2 to 97.1)   33.3--99.0
   All clinical populations          62                11 071    0.0--100               72.5                               72.4 (67.4 to 77.2)      1847.3 (p\<0.001)     96.7 (96.2 to 97.1)   31.3--98.8
  Other populations                                                                                                                                                                             
   HIV positive patients             19                2493      76.0--97.0             90.1                               89.0 (86.3 to 91.5)      65.2 (p\<0.001)       72.4 (56.4 to 82.6)   77.2--97.1
   Female sex workers                6                 1062      60.9--99.0             78.3                               83.2 (66.9 to 94.8)      171.7 (p\<0.001)      97.1 (95.4 to 98.1)   18.5--100
   Men who have sex with men         10                6074      52.1--91.0             68.0                               67.0 (59.9 to 73.8)      286.9 (p\<0.001)      96.9 (95.6 to 97.8)   39.3--89.5
   Prisoners                         9                 357       67.0--86.4             77.0                               80.4 (75.8 to 84.6)      5.7 (p=0.680)         0.0 (0.0 to 50.6)     74.9--84.4
  European subregion/country                                                                                                                                                                    
   Northern Europe                   161               47 202    13.0--100              67.2                               57.7 (54.4 to 60.9)      7721.3 (p\<0.001)     97.9 (97.8 to 98.1)   19.3--91.4
   Eastern Europe                    64                12 260    0.0--100               85.5                               78.7 (74.1 to 83.0)      2153.3 (p\<0.001)     97.1 (96.7 to 97.4)   37.8--100
   Southern Europe                   77                16 063    3.6--100               81.4                               77.2 (71.7 to 82.3)      4677.4 (p\<0.001)     98.4 (98.2 to 98.5)   24.8--100
   Western Europe                    264               68 556    0.0--95.7              67.9                               66.1 (63.1 to 69.0)      17 258.0 (p\<0.001)   98.5 (98.4 to 98.5)   18.8--98.9
   Israel                            35                7060      22.2--94.9             67.9                               64.8 (58.8 to 70.7)      910.9 (p\<0.001)      96.3 (95.5 to 96.9)   28.3--93.6
   Turkey                            17                3076      30.4--99.0             92.3                               87.9 (79.8 to 94.2)      557.2 (p\<0.001)      97.1 (96.3 to 97.8)   43.4--100
   Mixed subregions                  4                 2295      55.3--76.7             71.7                               68.9 (56.9 to 79.8)      101.7 (p\<0.001)      97.0 (94.8 to 98.3)   13.5--100
  Sex                                                                                                                                                                                           
   Women                             258               62 162    2.0--100               72.1                               69.5 (66.5 to 72.5)      16 531.4 (p\<0.001)   98.4 (98.4 to 98.5)   20.8--99.8
   Men                               194               49 887    7.5--100               65.5                               63.3 (59.7 to 66.7)      12 372.9 (p\<0.001)   98.4 (98.3 to 98.5)   16.8--97.9
   Mixed sexes                       170               44 463    0.0--100               70.0                               68.8 (65.3 to 72.2)      9860.3 (p\<0.001)     98.3 (98.2 to 98.4)   23.0--99.1
  Age group (years)                                                                                                                                                                             
   \<20                              147               32 492    0.0--100               36.4                               39.3 (35.9 to 42.7)      5530.3 (p\<0.001)     97.4 (97.1 to 97.6)   6.8--78.5
   20--30                            73                13 156    32.0--100              66.7                               66.7 (62.0 to 71.1)      2204.1 (p\<0.001)     96.7 (96.3 to 97.1)   26.8--96.1
   30--40                            60                9594      40.0--96.9             73.0                               72.9 (69.3 to 76.3)      854.6 (p\<0.001)      93.1 (91.8 to 94.2)   44.1--94.0
   40--50                            25                5188      49.0--96.6             76.0                               74.5 (68.5 to 80.0)      487.7 (p\<0.001)      95.1 (93.7 to 96.1)   42.3--96.4
   \>50                              47                16 363    57.1--100              84.0                               82.9 (78.8 to 86.6)      1546.3 (p\<0.001)     97.0 (96.5 to 97.4)   52.2--99.6
   Mixed                             270               79 719    0.0--100               78.2                               77.1 (75.1 to 79.1)      11 355.6 (p\<0.001)   97.6 (97.5 to 97.8)   41.1--98.9
  Year or publication range                                                                                                                                                                     
   \<2000                            127               23 076    0.0--100               71.6                               70.0 (66.0 to 73.9)      4826.5 (p\<0.001)     97.4 (97.2 to 97.6)   25.2--99.2
   2000--2010                        361               86 175    6.0--100               72.0                               69.3 (67.0 to 71.5)      1891.5 (p\<0.001)     97.1 (98.0 to 98.2)   24.7--98.8
   \>2010                            134               47 261    0.0--100               62.7                               59.7 (55.1 to 64.3)      13 668.2 (p\<0.001)   99.0 (99.0 to 99.1)   11.0--98.2
  Age bracket                                                                                                                                                                                   
   All children                      104               24 097    0.0--82.0              31.5                               32.5 (29.4 to 35.7)      2698.1 (p\<0.001)     96.2 (95.7 to 96.6)   7.1--65.4
   All adults                        505               126 430   0.0--100               76.0                               74.4 (72.8 to 76.0)      19 321.3 (p\<0.001)   97.4 (97.3 to 97.5)   37.1--98.3
   All age mixed                     13                5985      30.4--68.6             53.7                               54.3 (47.4 to 61.0)      301.1 (p\<0.001)      96.0 (94.5 to 97.1)   27.4--79.9
   All studies                       622               156 512   0.0--100               70.0                               67.4 (65.5 to 69.3)      39 384.9 (p\<0.001)   98.4 (98.4 to 98.5)   20.2--99.1

\*The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures (here, HSV-1 seroprevalence).

†I^2^ is a measure assessing the magnitude of between study variation that is due to true differences in HSV-1 seroprevalence across studies rather than sampling variation.

‡Prediction interval is a measure quantifying the 95% interval of the distribution of true HSV-1 seroprevalence around the estimated pooled mean.

HSV-1, herpes simplex virus type 1.

Pooled mean estimates for HSV-1 seroprevalence {#s3-3}
----------------------------------------------

[Table 2](#T2){ref-type="table"} shows the seroprevalence meta-analyses. Overall pooled mean seroprevalence (across all measures, n=622) was 67.4% (95% CI 65.5% to 69.3%). The pooled mean seroprevalences for healthy (n=101) and for clinical (n=3) children were 32.4% (95% CI 29.2% to 35.6%) and 37.8% (95% CI 28.3% to 47.8%), respectively. The pooled mean for healthy (n=402) and for clinical (n=59) adults was 73.7% (95% CI 71.9% to 75.4%) and 73.8% (95% CI 68.9% to 78.5%), respectively.

Across age groups, pooled mean seroprevalence increased gradually from 39.3% (n=147, 95% CI 35.9% to 42.7%) in those aged \<20 years, followed by 66.7% (n=73, 95% CI 62.0% to 71.1%) in 20--30 year olds, 72.9% (n=60, 95% CI 69.3% to 76.3%) in 30--40 year olds, 74.5% (n=25, 95% CI 68.5% to 80.0%) in 40--50 year olds, to 82.9% (n=47, 95% CI 78.8% to 86.6%) in those aged \>50 years.

Across European subregions/countries, the pooled mean seroprevalence was lowest at 57.7% (n=161, 95% CI 54.4% to 60.9%) in Northern Europe, followed by 64.8% (n=35, 95% CI 58.8% to 70.7%) in Israel, 66.1% (n=264, 95% CI 63.1% to 69.0%) in Western Europe, 77.2% (n=77, 95% CI 71.7% to 82.3%) in Southern Europe, 78.7% (n=64, 95% CI 74.1%--83.0%) in Eastern Europe and 87.9% (n=17, 95% CI 79.6% to 94.2%) in Turkey.

Heterogeneity was evident in the majority of meta-analyses (p value \<0.001; [table 2](#T2){ref-type="table"}), and affirmed by wide prediction intervals. Variation in seroprevalence was due to true variation in seroprevalence as opposed to sampling variation (I^2^ \>50%). Forest plots for meta-analyses across age groups can be found in online [supplementary figure s1](#SP1){ref-type="supplementary-material"}. Sensitivity analyses using the logit transformation and the multilevel meta-analytic model generated overall similar results (online [supplementary table s5](#SP1){ref-type="supplementary-material"}).

Predictors of HSV-1 seroprevalence {#s3-4}
----------------------------------

[Table 3](#T3){ref-type="table"} and online [supplementary table s6](#SP1){ref-type="supplementary-material"} show seroprevalence meta-regression analyses. Four multivariable models were conducted due to collinearity between age bracket and age group, as well as between year of publication as a categorical variable and year of publication as a continuous linear term. Each multivariable model included nine eligible variables (yielding a p value \<0.1 in the univariable analysis).

###### 

Univariable and multivariable meta-regression models for herpes simplex virus type 1 seroprevalence in Europe, with time trend assessed categorically by decade

                                      Outcome measure   Sample    Univariable analysis   Multivariable analysis\*                                                                           
  ----------------------------------- ----------------- --------- ---------------------- -------------------------- --------- ------- --------------------- --------- --------------------- ---------
  Population characteristics                                                                                                                                                                
  Age bracket                                                                                                                                                                               
   Children                           104               24 097    1.00                   --                         \<0.001   50.16   1.00                  --        --                    --
   Adults                             505               126 430   2.23 (2.07 to 2.4)     \<0.001                                      2.11 (1.98 to 2.26)   \<0.001   --                    --
   Age mixed                          13                5985      1.67 (1.38 to 2.02)    \<0.001                                      1.43 (1.21 to 1.69)   \<0.001   --                    --
  Age group (years)                                                                                                                                                                         
   \<20                               147               32 492    1.00                   --                         \<0.001   48.69   --                    --        1.00                  --
   20--30                             73                13 156    1.70 (1.54 to 1.87)    \<0.001                                      --                    --        1.62 (1.49 to 1.76)   \<0.001
   30--40                             60                9594      1.91 (1.73 to 2.11)    \<0.001                                      --                    --        1.82 (1.67 to 1.99)   \<0.001
   40--50                             25                5188      1.95 (1.70 to 2.24)    \<0.001                                      --                    --        1.93 (1.70 to 2.18)   \<0.001
   \>50                               47                16 363    2.17 (1.94 to 2.42)    \<0.001                                      --                    --        2.29 (2.06 to 2.53)   \<0.001
   Mixed                              270               79 719    1.99 (1.86 to 2.13)    \<0.001                                      --                    --        1.91 (1.79 to 2.04)   \<0.001
  Sex                                                                                                                                                                                       
   Women                              258               62 162    1.00                   --                         0.027     1.27    1.00                  --        1.00                  --
   Men                                194               49 887    0.91 (0.83 to 0.98)    0.020                                        0.93 (0.87 to 0.98)   0.006     0.91 (0.86 to 0.96)   0.001
   Mixed                              170               44 463    1.01 (0.93 to 1.10)    0.773                                        0.98 (0.92 to 1.05)   0.633     0.93 (0.87 to 1.00)   0.039
  Population type                                                                                                                                                                           
   Healthy                            516               135 456   1.00                   --                         \<0.001   3.71    1.00                  --        1.00                  --
   Clinical                           62                11 071    1.16 (1.03 to 1.30)    0.014                                        1.05 (0.96 to 1.15)   0.256     1.06 (0.97 to 1.16)   0.179
   Other                              44                9985      1.33 (1.16 to 1.52)    \<0.001                                      1.24 (1.13 to 1.36)   \<0.001   1.22 (1.11 to 1.34)   \<0.001
  European subregion/country                                                                                                                                                                
   Northern Europe                    161               47 202    1.00                   --                         \<0.001   8.78    1.00                  --        1.00                  --
   Eastern Europe                     64                12 260    1.42 (1.26 to 1.61)    \<0.001                                      1.54 (1.39 to 1.72)   \<0.001   1.54 (1.39 to 1.72)   \<0.001
   Southern Europe                    77                16 063    1.34 (1.19 to 1.51)    \<0.001                                      1.37 (1.25 to 1.49)   \<0.001   1.36 (1.25 to 1.49)   \<0.001
   Western Europe                     264               68 556    1.16 (1.06 to 1.26)    0.001                                        1.24 (1.16 to 1.32)   \<0.001   1.20 (1.12 to 1.28)   \<0.001
   Israel                             35                7060      1.17 (0.99 to 1.37)    0.053                                        1.29 (1.16 to 1.44)   \<0.001   1.22 (1.09 to 1.37)   0.001
   Turkey                             17                3076      1.56 (1.26 to 1.93)    \<0.001                                      1.37 (1.12 to 1.67)   0.002     1.38 (1.15 to 1.72)   0.001
   Mixed subregions                   4                 2295      1.28 (0.84 to 1.95)    0.239                                        1.14 (0.86 to 1.51)   0.339     1.13 (0.85 to 1.50)   0.386
  Country's income                                                                                                                                                                          
   UMIC                               46                8893      1.00                   --                         \<0.001   3.68    1.00                  --        1.00                  --
   HIC‡                               576               147 619   0.74 (0.65 to 0.84)    \<0.001                                      0.92 (0.80 to 1.05)   0.245     0.92 (0.81 to 1.06)   0.274
  Study methodology characteristics                                                                                                                                                         
  Assay type                                                                                                                                                                                
   Western blot                       52                6551      1.00                   --                         0.021     0.92    1.00                  --        1.00                  --
   ELISA                              518               137 318   0.84 (0.74 to 0.96)    0.011                                        0.94 (0.86 to 1.03)   0.258     1.00 (0.91 to 1.10)   0.977
   Others                             52                12 643    0.80 (0.67 to 0.95)    0.013                                        0.85 (0.73 to 0.98)   0.031     0.89 (0.77 to 1.03)   0.131
  Sample size§                                                                                                                                                                              
   \<100                              46                1795      1.00                   --                         0.016     1.19    1.00                  --        1.00                  --
   ≥100                               576               154 717   0.84 (0.73 to 0.96)    0.016                                        0.91 (0.82 to 1.01)   0.090     0.94 (0.84 to 1.04)   0.240
  Sampling method                                                                                                                                                                           
   Probability based                  267               67 601    1.00                   --                         0.395     0.00    --                    --        --                    --
   Non- probability based             355               88 911    1.03 (0.96 to 1.11)    0.395                                        --                    --        --                    --
  Response rate                                                                                                                                                                             
   ≥80                                37                11 985    1.00                   --                         0.083     0.42    1.00                  --        1.00                  --
   \<80                               94                29 203    0.84 (0.71 to 0.99)    0.049                                        0.96 (0.84 to 1.10)   0.606     0.90 (0.79 to 1.02)   0.123
   Unclear                            491               115 324   0.93 (0.80 to 1.08)    0.326                                        0.98 (0.89 to 1.09)   0.768     0.96 (0.86 to 1.06)   0.387
  Year of publication range                                                                                                                                                                 
   \<2000                             127               23 076    1.00                   --                         0.001     2.22    1.00                  --        1.00                  --
   2000--2010                         361               86 175    0.97 (0.88 to 1.06)    0.482                                        0.89 (0.83 to 0.96)   0.003     0.91 (0.84 to 0.98)   0.010
   \>2010                             134               47 261    0.83 (0.74 to 0.93)    0.001                                        0.85 (0.78 to 0.93)   \<0.001   0.87 (0.80 to 0.95)   0.002

\*Variance explained by the final multivariable model 1 (adjusted R*^2^*)=63.80%.

†Variance explained by the final multivariable model 2 (adjusted R*^2^*)=63.69%.

‡High income country category includes one measure representing 12 European countries.

§Sample size denotes the sample size of the study population found in the original publication.

ARR, adjusted risk ratio; ELISA, enzyme linked immunosorbent type specific assay; HIC, high income country; HSV-1, herpes simplex virus type 1; RR, risk ratio; UMIC, upper middle income country.

The first model in [table 3](#T3){ref-type="table"} included age bracket, sex, population type, European subregion/country, country's income, assay type, sample size, response rate and year of publication range. This model explained 63.80% of the seroprevalence variation. HSV-1 seroprevalence was 2.11-fold (95% CI 1.98 to 2.26) higher in adults compared with children, and 0.93-fold (95% CI 0.87 to 0.98) lower in men compared with women. Compared with Northern Europe, HSV-1 seroprevalence was 1.24-fold (95% CI 1.16 to 1.32) higher in Western Europe, 1.29-fold (95% CI 1.16 to 1.44) higher in Israel, 1.36-fold (95% CI 1.25 to 1.49) higher in Southern Europe, 1.37-fold (95% CI 1.12 to 1.67) higher in Turkey and 1.54-fold (95% CI 1.39 to 1.72) higher in Eastern Europe. Evidence of a decline in seroprevalence over time was significant. Compared with the years before 2000, HSV-1 seroprevalence was 0.89-fold (95% CI 0.83 to 0.96) and 0.85-fold (95% CI 0.78 to 0.93) lower between the years 2000--2010 and the years after 2010, respectively.

The second model incorporated age group in proxy of age bracket, explained 63.69% of the seroprevalence variation and yielded similar results ([table 3](#T3){ref-type="table"}). Compared with those aged \<20 years, HSV-1 seroprevalence was 1.62-fold (95% CI 1.49 to 1.76) higher in 20--30 year olds, 1.82-fold (95% CI 1.67 to 1.99) higher in 30--40 year olds, 1.93-fold (95% CI 1.70 to 2.18) higher in 40--50 year olds and 2.29-fold (95% CI 2.06 to 2.53) higher in those aged \>50 years.

Online [supplementary table s6](#SP1){ref-type="supplementary-material"} includes the univariable and multivariable analyses using year of publication as a continuous variable. The results were similar to those observed in the two models listed above. The models showed evidence of a decline in HSV-1 seroprevalence of 0.99-fold (95% CI 0.99 to 1.00) per year.

These analyses were conducted using year of publication instead of year of data collection for completeness---13% of studies had no specified year of data collection. With imputation using year of publication adjusted for median difference with year of data collection, the declining trend did not reach statistical significance. Sensitivity analyses using the multilevel meta-analytic model supported the findings of the baseline analysis results, but some of the effects had wider CI (online [supplementary table s7](#SP1){ref-type="supplementary-material"}).

HSV-1 isolation in genital ulcer disease and in genital herpes: overview and meta-analyses {#s3-5}
------------------------------------------------------------------------------------------

Online [supplementary table s8](#SP1){ref-type="supplementary-material"} and [table 4](#T4){ref-type="table"} summarise the extracted proportion measures of HSV-1 detection in GUD and in genital herpes; [table 4](#T4){ref-type="table"} also includes the results of the meta-analyses.

###### 

Pooled proportions of herpes simplex virus type 1 virus isolation in clinically diagnosed genital ulcer disease and in clinically diagnosed genital herpes in Europe

  Population                                          Outcome measure   Sample   Proportion of HSV-1 detection   Pooled proportion of HSV-1 detection   Heterogeneity measures                                             
  --------------------------------------------------- ----------------- -------- ------------------------------- -------------------------------------- ------------------------ ------------------- --------------------- ------------
  Patients with clinically diagnosed GUD                                                                                                                                                                                   
   All patients with GUD                              4                 800      4.7--39.8                       8.5                                    13.6 (4.1 to 27.1)       58.1 (p\<0.001)     94.8 (89.0 to 97.4)   0.0--85.5
  Patients with clinically diagnosed genital herpes                                                                                                                                                                        
   Sex                                                                                                                                                                                                                      
   Women                                              62                4933     6.0--89.6                       43.5                                   42.0 (37.4 to 46.7)      615.3 (p\<0.001)    90.2 (88.0 to 91.8)   11.6--76.0
   Men                                                56                3578     0.0--75.0                       26.6                                   24.1 (19.8 to 28.6)      461.1 (p\<0.001)    88.1 (85.3 to 90.3)   1.8--58.4
   Mixed                                              44                32 570   4.6--81.8                       45.0                                   35.8 (32.1 to 39.6)      1778.5 (p\<0.001)   97.6 (97.2 to 97.9)   14.7--60.3
  Age group (years)                                                                                                                                                                                                         
   \<20                                               3                 157      45.4--66.6                      53.3                                   52.1 (39.1 to 64.9)      3.2 (p=0.197)       38.5 (0.0 to 80.8)    0.0--100
   20--30                                             6                 643      27.3--54.9                      38.5                                   39.9 (32.2 to 47.8)      18.3 (p=0.003)      72.7 (37.1 to 88.1)   17.1--65.2
   30--40                                             2§                102      34.0--51.8                      43.3                                   43.5 (27.4 to 60.3)§     --                  --                    --
   Mixed                                              151               40 179   0.0--89.6                       33.3                                   33.4 (30.9 to 39.6)      3497.8 (p\<0.001)   95.7 (95.3 to 96.1)   9.5--62.8
  Genital herpes episode status                                                                                                                                                                                             
   First episode genital herpes                       13                1366     31.0--75.0                      49.0                                   49.3 (42.2 to 56.4)      66.1 (p\<0.001)     81.8 (70.1 to 89.0)   24.5--74.2
   Recurrent genital herpes                           11                893      1.0--77.3                       10.0                                   13.7 (5.8 to 24.1)       152.7 (p\<0.001)    92.5 (90.2 to 95.6)   0.060.5
   Unspecified status                                 138               38 822   0.0--89.6                       34.7                                   34.7 (32.3 to 37.1)      2730.0 (p\<0.001)   95.0 (94.4 to 95.5)   12.3--61.2
  European subregion/country                                                                                                                                                                                                
   Northern Europe                                    131               38 843   1.0--89.6                       34.8                                   35.0 (32.5 to 37.6)      2854.7 (p\<0.001)   95.4 (95.0 to 95.9)   12.1--62.2
   Eastern Europe                                     2§                100      34.9--63.1                      49.0                                   49.3 (22.7 to 76.0)§     --                  --                    --
   Southern Europe                                    8                 286      0.0--50.0                       15.4                                   18.2 (7.3 to 23.1)       39.1 (p\<0.001)     82.1 (66.0 to 90.6)   0.0--68.9
   Western Europe                                     5                 462      7.5--37.1                       25.0                                   21.8 (11.7 to 33.8)      33.2 (p\<0.001)     88.0 (74.4 to 94.3)   0.0--70.2
   Israel                                             4                 605      21.0--72.7                      54.0                                   50.3 (20.8 to 79.7)      142.4 (p\<0.001)    97.9 (96.5 to 98.7)   0.0--100
   Mixed subregions                                   12                785      6.0--57.5                       37.9                                   30.8 (19.5 to 43.4)      140.4 (p\<0.001)    92.2 (88.2 to 94.8)   0.0--79.5
  Year or publication range                                                                                                                                                                                                 
   \<2000                                             74                5072     0.0--81.8                       34.8                                   33.4 (28.3 to 38.8)      1099.7 (p\<0.001)   93.4 (92.3 to 94.3)   1.7--78.1
   2000--2010                                         53                8727     4.0--77.3                       25.0                                   29.4 (24.6 to 34.5)      1196.4 (p\<0.001)   95.7 (94.9 to 96.3)   3.0--67.1
   \>2010                                             35                27 282   18.7--89.6                      42.8                                   46.0 (43.6 to 48.3)      280.0 (p\<0.001)    87.9 (84.1 to 90.7)   35.6--56.5
   All patients with genital herpes                   162               41 081   0.0--89.7                       34.7                                   34.1 (31.7 to 36.5)      3529.8 (p\<0.001)   95.4 (95.0 to 95.8)   10.1--63.2

\*The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures (here, proportions of HSV-1 virus isolation).

†I^2^ is a measure assessing the magnitude of between study variation that is due to true differences in proportions of HSV-1 virus isolation across studies rather than sampling variation.

‡Prediction interval is a measure quantifying the 95% interval of the distribution of true proportions of HSV-1 virus isolation around the estimated pooled mean.

§No meta-analysis was done as number of studies was \<3. The two study samples were merged to yield one sample size, for which the 95% CI was calculated.

GUD, genital ulcer disease; HSV-1, herpes simplex virus type 1.

In GUD cases (n=4), proportion measures ranged between 4.7% and 39.8% with a median of 8.5% and a pooled proportion of 13.6% (95% CI 4.1% to 27.1%). In genital herpes cases (n=162), proportion measures ranged between 0.0% and 89.7% with a median of 34.7% and a pooled proportion of 34.1% (95% CI 31.7% to 36.5%) ([table 4](#T4){ref-type="table"}).

Among women, proportions of HSV-1 detection in genital herpes ranged between 6.0% and 89.6% with a median of 43.5% and a pooled mean of 42.0% (n=62, 95% CI 37.4% to 46.7%), and among men, between 0.0% and 75.0% with a median of 26.6% and a pooled mean of 24.1% (n=56, 95% CI 19.8% to 28.6%).

In first episode genital herpes cases, proportions of HSV-1 detection ranged between 31.0% and 75.0% with a median of 49.0% and a pooled mean of 49.3% (n=13, 95% CI 42.2% to 56.4%). In recurrent genital herpes cases, proportions ranged between 1.0% and 77.3% with a median of 10.0% and a pooled mean of 13.7% (n=11, 95% CI 5.8% to 24.1%)

[Table 4](#T4){ref-type="table"} lists summaries for other population classifications. The majority of meta-analyses showed evidence of heterogeneity with I^2^ \>50%, and large prediction intervals. The two key forest plots (all GUD and all genital herpes) are available in online [supplementary figure s2](#SP1){ref-type="supplementary-material"}. Sensitivity analyses using the logit transformation and the multilevel meta-analytic model generated overall similar results (online [supplementary table s9](#SP1){ref-type="supplementary-material"}).

Predictors of HSV-1 detection in genital herpes {#s3-6}
-----------------------------------------------

[Table 5](#T5){ref-type="table"} shows meta-regression analyses for proportion measures of HSV-1 virus isolation in genital herpes. In the univariable analyses, sex, genital herpes episode status, year of publication and year of publication range had a p value\<0.1 and thus were included in the multivariable analyses. Two multivariable models were constructed due to collinearity between year of publication range (categorical variable) and year of publication (continuous variable).

###### 

Univariable and multivariable meta-regression models for proportion measures of herpes simplex virus type 1 virus isolation in clinically diagnosed genital herpes in Europe

                                  Outcome measure   Sample   Univariable analysis   Multivariable analysis                                                                           
  ------------------------------- ----------------- -------- ---------------------- ------------------------ --------- ------- --------------------- --------- --------------------- ---------
  Age group (years)                                                                                                                                                                  
   \<20                           3                 157      1.00                   --                       0.394     0.00    --                    --        --                    --
   20--30                         6                 643      0.71 (0.29 to 1.71)    0.447                                      --                    --        --                    --
   30--40                         2                 102      0.78 (0.25 to 2.44)    0.675                                      --                    --        --                    --
   Mixed                          151               40 179   0.58 (0.28 to 1.21)    0.147                                      --                    --        --                    --
  Sex                                                                                                                                                                                
   Women                          62                4933     1.00                   --                       0.001     11.27   1.00                  --        1.00                  --
   Men                            56                3578     0.63 (0.50 to 0.80)    \<0.001                                    0.62 (0.50 to 0.76)   \<0.001   0.61 (0.49 to 0.75)   \<0.001
   Mixed                          44                32 570   0.63 (0.65 to 1.02)    0.074                                      0.81 (0.65 to 1.00)   0.061     0.81 (0.66 to 1.01)   0.067
  Genital herpes episode status                                                                                                                                                      
   First episode genital herpes   13                1366     1.00                   --                       \<0.001   12.19   1.00                  --        1.00                  --
   Recurrent genital herpes       11                893      0.27 (0.17 to 0.47)    \<0.001                                    0.29 (0.49 to 0.93)   0.016     0.27 (0.17 to 0.44)   \<0.001
   Unspecified status             138               38 822   0.68 (0.49 to 0.95)    0.026                                      0.67 (0.49 to 0.92)   0.016     0.66 (0.48 to 0.89)   0.008
  European subregion/country                                                                                                                                                         
   Northern Europe                131               38 843   1.00                   --                       0.397     0.61    --                    --        --                    --
   Eastern Europe                 2                 100      1.44 (0.59 to 3.46)    0.417                                      --                    --        --                    --
   Southern Europe                8                 286      0.79 (0.44 to 1.40)    0.424                                      --                    --        --                    --
   Western Europe                 5                 462      0.63 (0.34 to 1.13)    0.119                                      --                    --        --                    --
   Israel                         4                 605      1.38 (0.74 to 2.60)    0.304                                      --                    --        --                    --
   Mixed subregions               12                785      0.89 (0.60 to 1.34)    0.600                                      --                    --        --                    --
  Sample sizec‡                                                                                                                                                                      
   \<100                          56                3905     1.00                   --                       0.591     0.00    --                    --        --                    --
   ≥100                           106               37 176   1.06 (0.85 to 1.32)    0.591                                      --                    --        --                    --
  Year of publication range                                                                                                                                                          
   \<2000                         74                5072     1.00                   --                       0.021     3.95    1.00                  --        --                    --
   2000--2010                     53                8727     0.86 (0.68 to 1.08)    0.193                                      0.94 (0.76 to 1.16)   0.555     --                    --
   \>2010                         35                27 282   1.26 (0.98 to 1.63)    0.070                                      1.26 (1.00 to 1.58)   0.049     --                    --
  Year of publication             162               41 081   1.01 (1.00 to 1.02)    0.043                    0.043     2.57    --                    --        1.01 (1.00 to 1.02)   0.014

\*Variance explained by the final multivariable model 1 (adjusted *R^2^*)=26.10%.

†Variance explained by the final multivariable model 2 (adjusted *R^2^*)=28.38%.

‡Sample size denotes the sample size of the study population found in the original publication.

ARR, adjusted risk ratio; HSV-1, herpes simplex virus type 1; RR, risk ratio.

The first model, including year of publication range, explained 26.10% of the proportion variation. Compared with women, the proportion of HSV-1 virus isolation in genital herpes was 0.62-fold (95% CI 0.50 to 0.79) lower in men. Genital herpes episode status showed a 0.29-fold (95% CI 0.49 to 0.93) lower proportion of HSV-1 detection in recurrent genital herpes compared with first episode genital herpes. Compared with the years before 2000, evidence of a 1.28-fold (95% CI 1.02 to 1.66) increase in HSV-1 detection in genital herpes was observed in the years after 2010. Similar results were observed when using imputed year of data collection as a categorical term in the model.

The second model, including year of publication as a linear term, had similar results and explained 14.99% of the proportion variation. Evidence of a 1.01-fold (95% CI 1.00 to 1.02) yearly increase in the proportion of HSV-1 detection in genital herpes was observed. Similar results were observed when using imputed year of data collection as a linear term in the model. Sensitivity analyses using the multilevel meta-analytic model supported the findings of the baseline analysis results, but some of the effects had wider CI (online [supplementary table s10](#SP1){ref-type="supplementary-material"}).

Quality assessment {#s3-7}
------------------

Online [supplementary table s11](#SP1){ref-type="supplementary-material"} summarises the quality assessment of seroprevalence studies (n=179). A total of 149 studies (83.2%) had high precision, 45 studies (25.1%) had low ROB in the sampling methodology domain and 12 studies (6.7%) had low ROB in the response rate domain. Only five studies (2.8%) had low ROB in both quality domains. Despite this, the meta-regression analyses ([table 3](#T3){ref-type="table"}) did not demonstrate an association between these study quality variables and HSV-1 seroprevalence, suggesting a minimal impact on the findings of this study.

Discussion {#s4}
==========

This comprehensive systematic review presented a detailed assessment of the epidemiology of HSV-1 in Europe. The results demonstrated that the epidemiology is in transition, with seroprevalence declining by 1% per year (online [supplementary table s6](#SP1){ref-type="supplementary-material"}), and HSV-1 detection in genital herpes increasing concurrently by 1% per year ([table 5](#T5){ref-type="table"}). With only two-thirds of the population being seropositive ([table 2](#T2){ref-type="table"}), HSV-1 seroprevalence in Europe is lower than that in most other regions,[@R6] and far lower than its historical level of nearly universal childhood infection still seen in other parts of the world,[@R6] notably Africa.[@R7]

The epidemiology of HSV-1 in Europe appears to be traversing a path seen already in North America,[@R17] with the declining seroprevalence possibly attributable to the general decrease in both family size and school crowding, as well as improved hygiene.[@R43] Although a seroprevalence decline is a positive development, there is cause for concern as a larger proportion of youth (as much as two-thirds) are reaching sexual debut uninfected ([table 2](#T2){ref-type="table"}), and are thus at risk of acquiring the infection genitally, through (mostly) oral--genital sex or genital--genital sex (genital herpes),[@R4] with a range of psychosexual adverse outcomes, such as effects on sexual relations and quality of life, depression, anxiety and shame.[@R45] This outcome is affirmed by the concurrency of seroprevalence decline with HSV-1 genital herpes increase ([table 3](#T3){ref-type="table"} and online [supplementary table s6](#SP1){ref-type="supplementary-material"} vs [table 5](#T5){ref-type="table"}).

HSV-1 seroprevalence increased with age, reflecting cumulative exposure, with age alone explaining about 50% of the seroprevalence variation ([table 3](#T3){ref-type="table"}). This confirms the general global age pattern seen in other regions,[@R6] where age typically explained half of the seroprevalence variation,[@R6] with the notable exception of Africa where age explained 80% of the variation.[@R7] There was also substantial difference in seroprevalence among those aged \<20 years and \>20 years ([Tables 2 and 3](#T2 T3){ref-type="table"}), suggesting that older cohorts had higher exposure in their youth, compared with the current young cohort, and affirming the decreasing trend in seroprevalence in recent decades.

Seroprevalence also varied by geographical location, with Eastern and Southern Europe as well as Turkey exhibiting higher seroprevalence rates compared with Northern and Western Europe ([tables 2 and 3](#T2 T3){ref-type="table"}), possibly mirroring the individual level association between HSV-1 infection and lower socioeconomic status.[@R43] This within region variation has also been observed in other regions,[@R6] with the exception of Africa[@R7] where the infection is homogenous and universal. Seroprevalence in Europe was also lower in men than women, in contrast with all other regions,[@R6] a finding that remains to be explained. Remarkably, clinical condition and country's income (after adjustment for European subregion) as well as study characteristics, did not appear to affect seroprevalence ([table 3](#T3){ref-type="table"}), probably highlighting that HSV-1 is a truly general population infection.

HSV-1 (vs HSV-2) detection in genital herpes was high at 34% and increasing ([table 4](#T4){ref-type="table"}), similar to that observed in North America,[@R5] but substantially higher than that observed in other regions.[@R7] This affirms that Europe has progressed in its epidemiological transition towards less oral acquisition and more genital acquisition, and that HSV-1 infection plays an increasing role as a sexually transmitted disease. Our results also demonstrated that women are more affected by HSV-1 genital herpes than men, possibly reflecting the age gap in sexual mixing, with younger women partnering with older men, or possibly reflecting biological susceptibility differences by sex.[@R51] Our results also demonstrated a much higher detection of HSV-1 in first episode genital herpes (at 49%) than in recurrent herpes (at only 10%) ([tables 4 and 5](#T4 T5){ref-type="table"}), supporting the fact that HSV-2 reactivates (in the genital tract) for a longer duration than HSV-1.[@R47]

This systematic review had limitations, primarily the unavailability of data for 25 of 53 European countries, and comparatively less data for GUD and genital herpes than for seroprevalence. For example, we expected to observe variation in HSV-1 detection in genital herpes by age or subregion, but no significant effect was found ([table 5](#T5){ref-type="table"}), possibly because of an insufficient number of studies. Included studies exhibited heterogeneity ([table 2](#T2){ref-type="table"}), but most seroprevalence variation (64%) was subsequently explained through meta-regressions ([table 3](#T3){ref-type="table"} and online [supplementary table s6](#SP1){ref-type="supplementary-material"}). Studies differed by assay type, sample size, sampling method and response rate, but none of these study characteristics appeared to affect seroprevalence ([table 3](#T3){ref-type="table"} and online [supplementary table s6](#SP1){ref-type="supplementary-material"}). Thus while these remain theoretical limitations, they do not appear to pose a barrier to the interpretation of the results of the study. It is also important to note that even though this study identified an increasing role for HSV-1 in genital herpes, this possibly could have been caused by a decreasing seroprevalence of the other competing cause, that is HSV-2 infection.

Conclusions {#s5}
===========

The epidemiology of HSV-1 in Europe is in transition and shifting away from its historical pattern of oral acquisition in childhood. As many as two-thirds of children are reaching sexual debut unexposed to this infection, and at risk of genital acquisition in adulthood. The transition is leading to more heterogeneous and variable transmission by age and geography, and an increasing role for HSV-1 in genital herpes. Seroprevalence is declining by 1% per year, and the contribution of HSV-1 to genital herpes is increasing, also by 1% per year. At present, half of first episode genital herpes is due to HSV-1 as opposed to HSV-2 infection. These findings highlight the importance of disease surveillance and monitoring of HSV-1 seroprevalence and genital herpes aetiology, and strengthen the case for a HSV-1 vaccine to limit transmission.
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